MS-DRG 019Surgical
Simultaneous Pancreas, Islet Cell and Kidney Transplant with Hemodialysis
Pre-MDC·Grouped by procedure·FY 2027
MS-DRG 019 is a Surgical Medicare Severity Diagnosis Related Group. For FY 2027 it carries a relative weight of 7.5493 with a geometric mean length of stay of 12.3 days and an arithmetic mean of 15.5 days. Hospitals use this grouping to determine reimbursement for inpatient stays under Medicare.
Advertisements
FY 2027 payment data
From Table 5 of the FY 2027 IPPS Final Rule (CMS).
- Relative weight:
- 7.5493 (payment multiplier vs. the average case (1.0))
- Geometric mean stay:
- 12.3 days (used for transfer payments)
- Average stay:
- 15.5 days (arithmetic mean)
- Post-acute transfer policy:
- No (not subject to it)
Procedure codes (27)
ICD-10-PCS procedures that can group a stay to DRG 019.
- 0FYG0Z0Transplantation of Pancreas, Allogeneic, Open Approach
- 0FYG0Z1Transplantation of Pancreas, Syngeneic, Open Approach
- 0FYG0Z2Transplantation of Pancreas, Zooplastic, Open Approach
- 0TY00Z0Transplantation of Right Kidney, Allogeneic, Open Approach
- 0TY00Z1Transplantation of Right Kidney, Syngeneic, Open Approach
- 0TY00Z2Transplantation of Right Kidney, Zooplastic, Open Approach
- 0TY10Z0Transplantation of Left Kidney, Allogeneic, Open Approach
- 0TY10Z1Transplantation of Left Kidney, Syngeneic, Open Approach
- 0TY10Z2Transplantation of Left Kidney, Zooplastic, Open Approach
- 3E030U0Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Open Approach
- 3E030U1Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Open Approach
- 3E033U0Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach
- 3E033U1Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach
- 3E0J3U0Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J3U1Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J7U0Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J7U1Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J8U0Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J8U1Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 5A1D701Performance of Urinary Filtration, Intermittent, Less than 6 Hours Per Day, Selective Cytopheresis
- 5A1D70ZPerformance of Urinary Filtration, Intermittent, Less than 6 Hours Per Day
- 5A1D801Performance of Urinary Filtration, Prolonged Intermittent, 6-18 hours Per Day, Selective Cytopheresis
- 5A1D80ZPerformance of Urinary Filtration, Prolonged Intermittent, 6-18 hours Per Day
- 5A1D901Performance of Urinary Filtration, Continuous, Greater than 18 hours Per Day, Selective Cytopheresis
- 5A1D90ZPerformance of Urinary Filtration, Continuous, Greater than 18 hours Per Day
- XW0337CIntroduction of Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 12
- XW033DAIntroduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10